ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Photodynamic therapy with ring-fused chlorins: a vision-preserving approach for retinoblastoma.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to use photodynamic therapy with ring-fused chlorins to treat Retinoblastoma, focusing on the therapeutic efficacy of photodynamic therapy and ensuring its safety.
methodsThree photosensitisers were evaluated in vitro using Y79-GFP-Luc cells to assess metabolic activity, viability, cell death mechanisms, and cell cycle modulation. In vivo efficacy was tested using an orthotopic xenograft model, assessed by optical coherence tomography, electroretinography, bioluminescence imaging, and immunohistochemistry.
resultsThe dihydroxymethyl derivative (Px1) emerged as the most potent (IC
conclusionOverall, the research confirmed that Px1-based photodynamic therapy has cytotoxic potential against Retinoblastoma, highlighting its promise as a treatment option for Retinoblastoma lesions while maintaining retinal integrity and function. Future studies should explore repeated or combination treatments to enhance tumour control in advanced disease, thereby accelerating the potential clinical translation of this approach for childhood Retinoblastoma.
Indexed as
Identifiers
41697626What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.